“Are the risk factors for early onset Alzheimer’s the same as late onset?” asks Domenico Praticò, MD, the Scott Richards North Star Foundation Chair for Alzheimer’s Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer’s Center at Temple (ACT), at the Lewis Katz School of Medicine at Temple University (LKSOM)
Clinical studies suggest the Mediterranean diet, and one of its main components, extra virgin olive oil (EVOO), improves cognitive function and slows Alzheimer's disease (AD) progression. Researchers will now investigate whether this is true even for people with a family history of AD and signs of genetic predisposition caused by dysfunction in the APOE gene.
The test alone will not provide enough information to reach a diagnosis of memory problems/cognitive decline. Only a trained physician can do it.
Since 2012, September has been celebrated as World Alzheimer’s Month. Back then, and only eleven years ago, an average of 2 out of 3 people had little understanding of Alzheimer's disease and associated dementias.
“There is abundant evidence of a link between contact sports, such as football, and dementia later in life,” comments Domenico Pratico, M.D., Director of the Alzheimer’s Center at Temple University (ACT).
A recent study shows that a protein called ABCA7 plays a functional role as a potential biological link between cholesterol and inflammation in Alzheimer’s disease. The new work was published online August 25 in the journal Cells.
A recent study has used Artificial Intelligence (AI) to reveal the remarkable potential of extra virgin olive oil (EVOO) in the fight against Alzheimer's disease (AD). Researchers combined AI technology, chemistry, and omics research to identify specific bioactive compounds in EVOO that show promising effects in treating and preventing AD.
A new approach could enhance memory and learning in individuals with Down syndrome by stabilizing a key component in the body's protein sorting system called the retromer complex.
A biomarker is a characteristic that can be measured and evaluated as an indicator of normal biological processes, pathogenetic processes, or pharmacologic responses to a therapeutic intervention. In the context of Alzheimer’s disease (AD), an AD biomarker indicates the presence or progression of the disease that may be altered by drug treatment, thereby demonstrating that it is hitting its target. Today, all clinical trials for Alzheimer’s disease utilize biomarkers of some form to assess whether the drug is actually affecting the disease in the brain.
The Lewis Katz School of Medicine created the Alzheimer’s Center at Temple from funds donated by Board of Trustees member Phil Richards earlier this month. Richards’s gift created the center and established the Scott Richards North Star Charitable Foundation Chair for Alzheimer’s Research.
Did you know that music might be able to connect you with your family members affected by Alzheimer's disease (AD) in a way that words cannot? Many studies have shown that music can evoke a response or a memory in people with Alzheimer's Disease.
The risk of side effects can rise if drugs are taken for conditions other than Alzheimer's disease (AD) treatment. Some sedatives and antidepressants can deteriorate cognitive function, make people drowsy and confused, and worsen cognitive impairment, which increases the risk of falls.
Alzheimer-like changes – marked by the build-up of harmful amyloid and tau proteins – occur in the brain in Down syndrome has been unclear. But now, in new research, scientists at the Lewis Katz School of Medicine at Temple University show that reduced efficiency of a key protein transport system is partly to blame.
Diagnosing Alzheimer's disease (AD) is a complex process that doesn't rely on a single test.
Alzheimer's disease is the most common form of dementia in the elderly. Memory loss and difficulty thinking worsen progressively, with some patients eventually becoming delusional, disoriented, and vulnerable to mood swings and depression. Finding ways to slow or reverse this progression, or even prevent symptoms from developing in the first place, are major goals in Alzheimer's research.
People may endure cognitive changes as they get older, including forgetfulness and a loss of their capacity for multitasking or concentration. Although these changes are typical, they can be upsetting for elderly people.
Alzheimer's disease is a debilitating condition that affects millions of people around the world, but there is also a lot of misinformation about it. One of the most common myths is that memory loss is a natural part of aging.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right